Keenova Therapeutics plc announced today that it reached a milestone: 100,000 patients with Peyronie's disease (PD) have been prescribed XIAFLEX® (collagenase clostridium histolyticum).1* ...

MALVERN, Pa., Nov. 20, 2024 /CNW/ -- Endo, Inc. ("Endo") (OTCQX: NDOI) announced today that John Elway will share an update about his Dupuytren's contracture patient journey, including his treatment ...

MALVERN, Pa., Feb. 17, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today the launch of its new branded television commercial, Steve's Journey. The campaign, featuring a real Dupuytren's ...

"PD Pool Hall" Explores the Men's Health Condition Through Real Patients and Real Talk Unscripted videos feature real Peyronie's disease (PD) patients discussing their experiences while shooting pool ...

MALVERN, Pa., March 12, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that a post hoc data analysis of a Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum, or ...

Hypersensitivity Reactions, Including Anaphylaxis: In the double-blind, placebo-controlled portions of the clinical trials in Peyronie's disease, a greater proportion of XIAFLEX-treated patients (4%) ...

MALVERN, Pa., Oct. 17, 2024 /PRNewswire/ -- Endo, Inc. ("Endo") (OTCQX: NDOI) announced today that seven new presentations related to Peyronie's disease, or PD, and XIAFLEX® (collagenase clostridium ...

MALVERN, Pa., Oct. 15, 2025 /PRNewswire/ -- Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced today that a presentation related to Peyronie's disease, or PD, and XIAFLEX ® (collagenase ...

MALVERN, Pa., Oct. 15, 2025 /PRNewswire/ -- Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced today that a presentation related to Peyronie's disease, or PD, and XIAFLEX ® (collagenase ...